ASF recently invited River 3 Renal Corp. to provide information about R3R01ASFSGS201, a phase 2 clinical trial open to Alport patients that is testing an investigational medication called R3R01. This video features a presentation about the study from Guido Magni, MD, PhD, followed by a Q&A session moderated by ASF's Patient Engagement Coordinator, Afton DeLucca. To learn more about this study, visit https://alportsyndrome.org/forpatien....